Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

20/09/2018 UAB’s researchers awarded by ERC 14/09/2018 More than 8,600 foreign companies in Catalonia 06/09/2018 SMEs: a European call for access to synchrotrons 27/07/2018 ICMAB and ICN2 work on the batteries of the future 20/07/2018 Molecular mimicry does not mislead ALBA! 13/07/2018 How about olive pits to filter the air?!
8 9 10 11 12 13 14 15 16 17 18